Logo.jpg
Biofrontera AG decides to delist ADS from Nasdaq to reduce complexity and costs
February 14, 2022 14:05 ET | Biofrontera AG
Leverkusen, Germany, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera AG (the “Company”) (Nasdaq: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, decided today its...
Logo.jpg
Biofrontera AG announces mediation results
November 19, 2021 08:45 ET | Biofrontera AG
Leverkusen, Germany, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (ISIN: DE0006046113) has been in mediation proceedings with Mr. Wilhelm K. T....
Logo.jpg
Biofrontera AG: Conference call to discuss third quarter 2021 financial results to be held on November 18, 2021
November 09, 2021 05:45 ET | Biofrontera AG
Leverkusen, Germany, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its...
Logo.jpg
Biofrontera reports financial results for the six months ended June 30, 2021
August 19, 2021 11:47 ET | Biofrontera AG
Leverkusen, Germany, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its...
Logo.jpg
Biofrontera AG: Conference call to discuss half-year 2021 financial results to be held on August 20, 2021
August 12, 2021 08:55 ET | Biofrontera AG
Leverkusen, Germany, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its...
Logo.jpg
Biofrontera reports preliminary revenue for the month of July 2021
August 09, 2021 09:00 ET | Biofrontera AG
Leverkusen, Germany, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported...
Logo.jpg
Biofrontera enters into license and supply agreement with Medac for the marketing of Ameluz® in Poland
July 23, 2021 04:15 ET | Biofrontera AG
Leverkusen, Germany, July 23, 2021 (GLOBE NEWSWIRE) -- Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), and Medac Gesellschaft für...
Logo.jpg
Biofrontera announces preliminary revenue for Q1 2021
April 08, 2021 10:30 ET | Biofrontera AG
Leverkusen, Germany, April 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported...
Logo.jpg
Biofrontera announces conference call to be held on April 13, 2021 to discuss fiscal year 2020 financial results
March 31, 2021 10:12 ET | Biofrontera AG
Leverkusen, Germany, March 31, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing...
Logo.jpg
Biofrontera announces conference call to be held on November 12, 2020 to discuss Q3 2020 financial results
November 02, 2020 08:00 ET | Biofrontera AG
Leverkusen, Germany, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its...